No impact seen on primary outcome among patients with asymptomatic severe aortic stenosis, myocardial fibrosis<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
THURSDAY, Oct. 31, 2024 (HealthDay News) — For patients with asymptomatic severe aortic stenosis and myocardial fibrosis, early aortic valve intervention does not impact all-cause death or unplanned aortic stenosis-related hospitalization compared with guideline-directed conservative management, according to a study published online Oct. 28 in the Journal of the American Medical Association<\/em> to coincide with the annual Transcatheter Cardiovascular Therapeutics conference, held from Oct. 27 to 30 in Washington, D.C.<\/p>\n Krithika Loganath, M.D., from the University of Edinburgh in the United Kingdom, and colleagues examined whether early valve intervention reduced the incidence of all-cause death or unplanned aortic stenosis-related hospitalization in asymptomatic patients with severe aortic stenosis and myocardial fibrosis in a trial conducted at 24 cardiac centers. A total of 224 eligible patients were enrolled and randomly assigned to receive early valve intervention with transcatheter or surgical aortic valve replacement or guideline-directed conservative management (113 and 111 patients, respectively).<\/p>\n The researchers found that the primary end point (composite of all-cause death or unplanned aortic stenosis-related hospitalization) occurred in 18 and 23 percent of patients in the early intervention and guideline-directed conservative management groups, respectively (hazard ratio [HR], 0.79; 95 percent confidence interval [CI], 0.44 to 1.43). No significant difference was seen in seven of nine prespecified secondary end points. All-cause death occurred in 14 and 13 percent of patients in the early-intervention and guideline-directed groups, respectively (HR, 1.22; 95 percent CI, 0.59 to 2.51). Unplanned aortic stenosis hospitalization occurred in 6 and 17 percent, respectively (HR, 0.37; 95 percent CI, 0.16 to 0.88).<\/p>\n “There was no demonstrable difference in the primary composite end point of all-cause mortality or unplanned aortic stenosis-related hospitalization,” the authors write.<\/p>\n Several authors disclosed ties to the biopharmaceutical industry.<\/p>\n Abstract\/Full Text<\/a><\/p>\n